NCT06992258 2026-03-17
FRUITION
Criterium, Inc.
Phase 2 Recruiting
Clinical Trials
19 trialsNCT05343013 2026-03-06
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07318389 2026-02-27
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Not yet recruiting
NCT04776148 2026-02-05
MK-7902-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT07361003 2026-01-22
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT05839951 2025-11-12
STAR-T
Bayer
Completed
NCT07212933 2025-10-08
RAK in GC
Chinese PLA General Hospital
Phase 2 Recruiting
NCT07085169 2025-07-25
Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
Ruijin Hospital
Phase 2 Recruiting
NCT05508737 2025-07-11
Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer
Yonsei University
Phase 1/2 Active not recruiting
NCT05201352 2025-05-30
TASKIN
Centre Georges Francois Leclerc
Phase 1/2 Active not recruiting
NCT04920032 2025-04-08
Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
University of California, Irvine
Phase 1 Recruiting
NCT04450836 2025-03-30
SOREGATT
UNICANCER
Phase 2 Terminated
NCT06882915 2025-03-19
Efficacy and Safety of Trifluridine/tipiracil (TAS-102) Combined with Bevacizumab and Putalimab in the Treatment of Patients with MCRC After Cytoreductive Surgery: a Single-arm, Single-center Clinical Study
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Not yet recruiting
NCT06711471 2024-12-02
Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06403709 2024-09-24
Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
NCT06202001 2024-04-02
Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Recruiting
NCT04074343 2024-02-02
TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
University of California, Irvine
Phase 1 Completed
NCT04854434 2023-11-03
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT03974594 2022-04-19
Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed